The UK and US have secured a landmark bilateral deal that will preserve zero levies on British drug exports going into the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to boost spending on medicines through the public health system. This commitment ensures that tariffs on these key products will stay at zero for a duration of the next three years.
This agreement follows recent statements to dramatically increase duties on patented drug products, with potential rates mentioned reaching one hundred percent.
"This agreement between the United Kingdom reinforces the international landscape for new treatments and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Trade Impact
Drugs are one of the Britain's biggest goods shipped to the United States, which is clearly the primary market for leading UK drugmakers.
Export figures show that in the 12 months prior to last September, the UK exported pharmaceutical products worth billions to the US. This amount made up 17.4% of all goods exports in that period.
"This guarantee protects jobs, increases capital expenditure and sets the stage for the UK to become a worldwide center for life sciences," a minister stated.
Detailed NHS Changes
The agreement entails several notable changes from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to increase overall health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to control costs will be limited at 15%. Previously, repayments topped twenty percent.
Industry Background
The pact follows a ongoing dispute between the drug companies and the British authorities over medicine costs and NHS adoption.
This friction were exacerbated by arguments that American customers were charged a premium for the equivalent treatments than people in the other developed nations.
Recently, several significant drug company projects in the UK have been delayed or cancelled, while major expansions have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had shrunk as a proportion of its total funding over the last ten years.
